Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Genfit Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Genfit wird ein jährliches Gewinn- und Umsatzwachstum von 54.7% bzw. 26.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 90.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.2% betragen.

Wichtige Informationen

54.7%

Wachstumsrate der Gewinne

148.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	20.0%
Wachstumsrate der Einnahmen	27.2%
Zukünftige Eigenkapitalrendite	8.2%
Analystenabdeckung	Low
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

May 23

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14

Is Genfit (EPA:GNFT) A Risky Investment?

Nov 28

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:GNFT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	105	38	N/A	N/A	4
12/31/2025	49	-21	17	17	5
12/31/2024	80	15	3	3	5
12/31/2023	34	-29	-58	-55	N/A
9/30/2023	32	-32	-55	-53	N/A
6/30/2023	29	-34	-52	-50	N/A
3/31/2023	28	-29	-62	-61	N/A
12/31/2022	26	-24	-73	-73	N/A
9/30/2022	60	12	4	4	N/A
6/30/2022	94	48	80	80	N/A
3/31/2022	90	58	90	90	N/A
12/31/2021	85	67	99	100	N/A
9/30/2021	46	14	10	11	N/A
6/30/2021	6	-39	-79	-79	N/A
3/31/2021	7	-70	-88	-88	N/A
12/31/2020	9	-101	-97	-96	N/A
9/30/2020	24	-84	-73	-71	N/A
6/30/2020	39	-67	-49	-46	N/A
3/31/2020	39	-66	-49	-47	N/A
12/31/2019	39	-65	-50	-48	N/A
9/30/2019	23	-80	-62	-60	N/A
6/30/2019	8	-94	-73	-71	N/A
3/31/2019	8	-87	-66	-64	N/A
12/31/2018	7	-80	-59	-56	N/A
9/30/2018	7	-75	N/A	N/A	N/A
6/30/2018	7	-70	-58	-56	N/A
3/31/2018	7	-63	-55	-53	N/A
12/31/2017	7	-56	-53	-50	N/A
9/30/2017	7	-50	N/A	N/A	N/A
6/30/2017	8	-44	N/A	-40	N/A
3/31/2017	7	-39	N/A	-34	N/A
12/31/2016	7	-34	N/A	-27	N/A
9/30/2016	6	-27	N/A	-23	N/A
6/30/2016	5	-21	N/A	-18	N/A
3/31/2016	5	-19	N/A	-16	N/A
12/31/2015	4	-17	N/A	-15	N/A
9/30/2015	5	-17	N/A	-17	N/A
6/30/2015	5	-17	N/A	-19	N/A
3/31/2015	6	-17	N/A	-17	N/A
12/31/2014	7	-17	N/A	-15	N/A
9/30/2014	7	-15	N/A	-15	N/A
6/30/2014	7	-14	N/A	-14	N/A
3/31/2014	6	-13	N/A	-11	N/A
12/31/2013	6	-13	N/A	-9	N/A
9/30/2013	6	-11	N/A	-8	N/A
6/30/2013	6	-9	N/A	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GNFT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1%).

Ertrag vs. Markt: GNFT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: GNFT wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: GNFTDie Einnahmen des Unternehmens (26.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (5.7% pro Jahr).

Hohe Wachstumseinnahmen: GNFTDie Einnahmen des Unternehmens (26.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GNFTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.2%).

Genfit Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

Consensus EPS estimates increase by 291%

Price target increased by 9.4% to €9.72

Consensus revenue estimates decrease by 21%

Price target increased by 9.4% to €9.70

Recent updates

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

New minor risk - Share price stability

Genfit S.A., Annual General Meeting, May 22, 2024

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

New minor risk - Profitability

Consensus EPS estimates increase by 291%

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Price target increased by 9.4% to €9.72

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Consensus revenue estimates decrease by 21%

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Price target increased by 9.4% to €9.70

New minor risk - Share price stability

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Price target decreased by 11% to €8.84

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to €9.20

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Consensus forecasts updated

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Consensus forecasts updated

Investor sentiment improved over the past week

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Consensus revenue estimates fall by 49%

Price target increased to €10.48

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 1,016%

Forecast to breakeven in 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.61 loss per share (vs €1.76 loss in FY 2019)

Price target increased to €8.30

Full year 2020 earnings released

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

Price target raised to €8.20

Genfit SA, Annual General Meeting, May 28, 2021

New 90-day high: €5.20

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

New 90-day high: €4.76

Robbins LLP Announces That Purchaser of Genfit SA American Depository Shares Filed Class Action Complaint Against the Company and Its Officers and Directors for Alleged Violations of the Securities Act of 1933

Is Genfit (EPA:GNFT) A Risky Investment?

Genfit Presents New Data at AASLD The Liver Meeting Digital Experience™

Analysts update estimates

Genfit and Labcorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

First half earnings released

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Genfit SA to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low: €3.86